Investors & Media
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and drug developers or learn how you can contribute to our mission.
Investor Opportunities
Contact UsLatest News
신주 발행 공고
May 2, 2023
채권자 이의제출 및 주권제출 공고
April 19, 2023
소규모 합병 공고
April 3, 2023
제7기 정기주주총회 소집공고(정정)
March 29, 2023
소규모 합병을 위한 기준일 공고
March 16, 2023
제7기 정기주주총회 소집공고
March 15, 2023
“미국 FDA 면역항암제 FB849 임상 1/2상 IND 승인”
December 20, 2022
“면역항암제 후보물질 KDDF 신약개발 지원과제 선정”
December 20, 2022
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
October 18, 2022
2022년 임시주주총회 소집공고(정정)
August 24, 2022
